MEDIUM confidence
Researched 2026-07-28 09:47 · profile: researcher
Programme Thesis
The DayOne Healthtech Accelerator funds early-stage healthtech ventures that bridge digital health, medtech, or techbio innovations with pharmaceutical R&D needs, providing equity-free mentorship and direct access to Basel's pharma ecosystem to accelerate real-world collaborations.
Selection Criteria
- Stage: pre-seed to Series A, with a prototype or product ready for pharma use within 12–18 months
- Relevance: solution addresses a clear pharma R&D problem (e.g., AI drug discovery, decentralized trials)
- Traction: evidence of validation, pilot interest, or early adoption
- Team: expertise and ability to execute, with pharma or healthtech background
- Scalability: potential for partnership or commercial collaboration with pharma companies
- Innovation: novelty and competitive advantage over existing approaches
Past Winners / Cohort Profiles
Past cohorts include digital health startups focused on AI-driven drug discovery, patient monitoring platforms, and clinical trial optimization tools. Named examples not found on page, but typical winners are early-stage ventures with a working prototype and a clear pharma partnership pathway.
Ideal Candidate Fingerprint
A pre-seed to Series A healthtech startup with a validated prototype that directly addresses a pharma R&D bottleneck, such as AI-powered drug resistance prediction or decentralized trial logistics. The team combines deep domain expertise in pharma and tech, has early traction (e.g., pilot with a pharma partner), and is ready to leverage Basel's ecosystem for rapid commercialization.
Recommended Framing
Eniola should position his venture as a techbio platform that uses AI and topological data analysis (TOPOLOGIX) to predict drug resistance and optimize pharma R&D, directly aligning with DayOne's focus on AI-powered drug discovery. Highlight the IMPRINT and TOPOLOGIX prototypes as ready-for-pharma tools, and leverage endorsements from Berridge, Gershman, and Daw to establish credibility. Emphasize the planned Servier pilot and the equity-free, pharma-neutral nature of the accelerator as a perfect fit for an independent researcher seeking industry collaboration.
Watch Out
Applicant is an independent researcher without a formal startup entity or co-founder team, which may be a disadvantage for an accelerator expecting a venture structure. The programme's Basel location and pharma network may require relocation or strong remote engagement plan. No named pharma partnership yet (only planned Servier pilot).